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A B S T R A C T 
Over the past three decades, many studies employing hollow-fiber liquid-phase microextraction (HF-LPME) 
bioanalytical methods have been published. The basic mechanism of extraction relies on the migration of the 
analytes through a liquid membrane sustained in the pores of the walls of a porous hollow fiber, and from there 
into an acceptor phase present in the lumen of the fiber. The mass transfer occurs by passive diffusion and it can 
be enhanced by using a carrier or applying an electrical potential across the phases. This type of extraction 
method presents many advantages over classical techniques, such as high preconcentration factor, clean 
extracts, and a green chemistry approach. Due to its advantages, and considering that no study systematically 
compiled the characteristics of the published methods in one single accessible source of information, 
the aim of this systematic review is to assess the data regarding bioanalytical methods, compile, and analyse 
the studies published until up to October of 2017. The data source used for the systematic review were Pubmed, 
Web of Science, and Science Direct, and 171 studies were included in the final review by two independent 
reviewers, resulting in a reliable and accessible source of information about bioanalytical methods employing 
HF-LPME. 
1. Introduction 
Sample preparation is a fundamental step in analytical chemistry, 
especially when the analytes are contained within complex matrices. 
The main purpose of this step is to simplify the matrix, enrich the 
analyte in the extract, and clean-up the sample [1]. The extraction is an 
equilibrium-based process related to the distribution of a solute or solutes 
between two phases [2] and is an essential step for many forensic 
toxicological analyses, which are normally related to complex biological 
matrices and low analyte concentrations [3,4]. 
The liquid-phase microextraction (LPME) methods are basically a 
miniaturization of liquid-liquid extraction (LLE): lower volumes of 
solvents are employed to extract the analytes from the sample, 
resulting in a reduction of solvent used and the analyst's exposure to 
potentially toxic substances. Many LPME methods were developed, 
including single-drop microextraction (SDME), continuous-flow microextraction 
(CFME), solvent-bar microextraction (SBME), dispersive 
liquid-liquid microextraction (DLLME), and hollow-fiber liquid-phase 
microextraction (HF-LPME). These methods overcome many of the 
drawbacks of traditional methods, being both fast and cheap. Whilst 
methods such as solid-phase extraction (SPE) and LLE consume a lot of 
organic solvent, HF-LPME uses microliters of solvent, presenting a 
green-chemistry approach. Besides that, it is highly selective and presents 
high pre-concentration factors, allowing the analyst to skip drying 
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and reconstituting steps. The use of a disposable fiber during the extraction 
also guarantees the absence of carryover and the clean-up of 
the sample by filtering it simultaneously to the extraction [3,5]. 
Many reviews have been written about HF-LPME [3,6–19], but none 
of them have focused on forensic applications of the technique, specifically. 
The present work is a systematic review of the up-to-date 
bioanalytical methods published using HF-LPME in the field of forensic 
toxicology. This methods compilation can be used as a quick guide for 
future methods development in the field. 
Criteria related to the 
publication 
Language of publication is not English 
Article was not available as full-text 
Criteria related to the 
extraction method 
Not HF-LPME 
Dynamic HF-LPME 
Criteria related to the 
purpose of the study 
Review article 
Pharmacokinetic study 
Protein-binding investigation 
Octanol/water distribution investigation 
Criteria related to the 
sample 
Analysis of environmental samples (e.g. water, soil) 
Analysis of food (e.g. vegetables, milk) 
Biological sample not from human source (e.g. rat blood) 
Criteria related to the 
analyte 
Analysis of metals and related compounds (e.g. organometallics) 
Analysis of compounds from the environmental exposure (e.g. 
substances from pollution of air or water) 
Analysis of compounds from dietary exposure (e.g. nitrites, 
preservatives) 
Endogenous substances with no forensic interest (e.g. angiotensin, 
vitamins, hormones, non-exposure biomarkers) 
Other substances with no forensic interest (e.g. cosmetics) 
Table 1. Exclusion criteria applied to the review. 
2.1. Method 
A review was completed to summarize the bioanalytical methods 
developed applying HF-LPME. For this purpose, the search covered 
three literature databases (Pubmed, Web of Science, and Science Direct) 
using the following search term: “microextraction AND hollow”. No 
search filters were used, except for Science Direct (in which the descriptors 
were restricted for the title, keywords, and abstract only). The 
snowballing technique was also employed in the search of articles of 
interest. The aim was to carry out a wide literature search. All articles 
containing bioanalytical methods (analysis of any xenobiotic and biotics 
in biological systems) were included in the first step of the review. 
No exclusion criteria concerning the date of the publication were applied 
(the search was performed for relevant studies up to October of 
2017). The exclusion criteria applied to reduce the initial pool of found 
articles to a final amount of articles that were included in the systematic 
review is summarized in Table 1 below. 
Studies with a different main purpose than developing methods 
using HF-LPME (such as protein-binding investigation) were included if 
they involved the development of a new HF-LPME method. Articles not 
available as full-text were attempted to be accessed by alternative 
sources before being excluded, such as inter-institutional request, author 
e-mailing, and search using other databases or Google. 
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Dynamic HF-LPME studies were excluded based on the different 
kinetics and dynamics of the system, as fresh solvent or sample is 
constantly introduced during the extraction in this technique. 
Two reviewers independently completed the review, searching and 
compiling the articles. After this, data from the articles was extracted 
into pre-defined tables. In case of difference between data extracted by 
the reviewers, the discordant data was discussed, and agreement 
reached before data was adopted. 
All of the data of interest was extracted, compiled (Tables 2 and 3), 
and discussed below. 
2.2. Results 
In the first step of the systematic review, 1002 potentially relevant 
articles were identified, of which 643 were excluded by reading the 
article title or abstract. From the remaining, 359 articles were evaluated 
and 188 articles were excluded upon reading the full text. The data of 
interest from the remaining 171 articles were compiled (Fig. 1) in 
Tables 2 and 3 and discussed. Some articles presented more than one 
HF-LPME method. 
 
Figure 5. Flowchart of the studies selection 
 
2.3. Forensic toxicological applications of HF-LPME 
Forensic toxicology plays an important role within the forensic 
sciences, and society has increasingly higher expectations of what forensic 
scientists in general can achieve. This is partly due to the so-called 
“CSI-effect”, and with the increasing number of cases related to new 
psychoactive substances (NPS), forensic toxicologists are under considerable 
pressure to test for an increasing range of drugs in smaller and 
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smaller specimen volumes [20–22]. Besides NPS, several other drugs 
can be detected in biological samples related to legal proceedings, such 
as ethanol, cocaine, benzodiazepines and other sedatives, opiates and 
LSD and other hallucinogenic drugs. A great concern linked to all drugs 
potentially related to legal proceedings is the high heterogeneity between 
the toxicokinetic and physical-chemical properties among them, 
resulting in challenging analyses, including complications during the 
sample preparation stages. Forensic Toxicologists aim to develop 
sample preparation methods that are simple, cheap and efficient, and 
HF-LPME is an excellent extraction method option that has not been 
extensively explored in the field of forensic toxicology yet. 
Extensive studies of the applicability of HF-LPME in the environmental 
field have been performed [15]. However, the number of published 
studies involving the analysis of drugs in biological samples is 
considerably lower. For applications in forensic toxicology, the number 
of publications is further reduced. Tables 2 and 3 summarize, in 
chronological order, applications of two and three-phase HF-LPME for 
biological sample analysis, respectively. 
2.4. Two-phase HF-LPME 
Forty-one bioanalytical methods that fit into the inclusion criteria 
have been developed to analyse drugs using 2-phase HF-LPME 
(Table 2); the first study was developed in 2000 by Rasmussen et al. 
[23]. 
2.4.1. Biological matrices 
Most of the studies used urine or plasma as matrices (30 and 21 out 
of 41, respectively) [5,23–58]. In post-mortem forensic toxicology the 
most commonly used biological specimen is whole blood, however, 
from all of the 2-phase HF-LPME studies, only 2 used whole blood 
[50,59]; limited detail was provided regarding the sample preparation 
in these studies. Two articles used oral fluid [54,60]; one of them [60] 
developed a method to extract cocaine and its metabolites, analytes 
commonly identified in forensic toxicology casework. The detection of 
drugs of abuse in oral fluid is becoming more common in workplace 
drug testing, and the method developed in this study resulted in a fast 
and sensitive method (10 min extraction time, and limits of detection of 
6-28 ng/mL by GC-PD-HID). Similar extraction conditions were applied 
to screen urine for the same analytes in another study [25], however, 
the extraction time was longer when oral fluid was used, probably due 
to the lower amount of sample available when compared to urine, and 
the lower concentration of the drugs in oral fluid. On the other hand, 
the method provided higher reproducibility for oral fluid compared 
with urine. Three studies described hair methods utilizing 2-phase HFLPME 
[39,52,61], but sample preparation was more complex. Some 
studies mentioned the difference in viscosity and protein-binding as 
reasons for different recoveries when using different biological matrices 
[24,32]. Most of the studies used the pure biological material or just a 
normal dilution or filtration, with no preceding step, however, one 
study [42] used protein precipitation in the sample preparation prior to 
HF-LPME, and demonstrated that this approach can be a useful tool for 
sample clean-up and releasing the analytes. 
2.4.2. Ionic strength 
Thirty-two out of the 41 publications included studies mentioned to 
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have used ionic strength as one of the optimized parameters 
[5,24,28,30–34,36–39] [41–49,51–59,61]. The salting-out effect is 
non-predictable and can either increase the extraction efficiency or 
decrease it due to the unpredictable effects on physical-chemical 
properties of the transition film present in the interface [1,15]. Eighteen 
of the studies that optimized the ionic strength decided not to use 
the salting-out technique in the final method [24,28,30,32,34,36, 
37,42,43,48,49,51–53,56,57,59] due to either the negative impact of 
increased salt concentration on the extraction, or the lack of effect of it; 
and 14 of them [5,31,33,38,39,41,44–47,54,55,58,61] decided to use 
the salting-out effect to improve extraction. All the studies that employed 
the salting-out effect, with exception of three [38,54,55], used 
sodium chloride. The result of the salting-out effect depends on the type 
of salt employed. The difference in the propensity of the salt to cause 
salting-out is related to different characteristics of the ions (structure, 
size, charge density, hydration, and dielectric constant) [1,15,62]. 
Meng et al. [54] saturated the donor phase with different salts, and 
sodium sulfate presented best results even though the concentrations 
that were compared were different; the concentrations of salt varied 
from 1% (w/v) to approximately 30% (w/v). Nine of the 41 studies 
[23,25–27,29,35,40,50,60] did not mention ionic strength as an optimization 
parameter. 
2.4.3. Ion pairing 
Ion pairing was used in only four out of the forty-one 2-phase HFLPME 
[26,49,57] studies to try to increase the extraction efficiency. 
Kramer et al. [26] compared two approaches: to extract the analyte 
(THC metabolite) by acidifying the sample, making the analyte neutral, 
and not using an ion-pairing agent; or to basify the sample and use an 
ion-pair agent to form neutral species with the ionized analyte. The 
second approach presented far better results in terms of peak area, and 
therefore was adopted to further extractions. According to the authors 
the higher ionic strength of the donor phase due to the ionization of the 
analyte and due to the presence of the ion pairing salt also contributed 
to less leakage of solvent from the fiber. 
2.4.4. Fiber 
Most of the 2-phase HF-LPME systems were built using polypropylene 
(PP) fibers with an internal diameter of 0.60 mm, wall 
thickness of 200 μm, pores of 0.2 μm, and 70% porosity. However, some 
studies used polyvinylidene difluoride (PVDF) [32,44,48,51] or polyethersulfone 
fibers [54], or PP fibers with different dimensions [26,33]. 
In 2001 [25] a group of researchers employed different fibers to extract 
cocaine and metabolites from urine, and PP presented larger peak areas 
and more reproducible results when compared to PVDF. No further 
information was given about the reason for the difference between the 
results using different fibers. Cui et al. [32] compared PP and PVDF 
fibers for the extraction of flunitrazepam, both differing only in wall 
thickness and porosity. The PVDF fiber presented a better solvent 
compatibility and faster extraction efficiency and operational accuracy 
due to its higher porosity. The thickness of the wall is an important 
factor that influences extraction efficiency and equilibrium time. Another 
study compared different fibers [44], two PVDF and one PP (all 
with different dimensions), and also attributed the better results of the 
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PVDF fiber to its higher porosity. The porosity of the PP fiber was not 
cited and the wall thickness, although an important parameter, was not 
explored in this study. An overall conclusion was that the dimensions of 
the fiber impacts on the extraction efficiency; solvent permeability and 
extraction time are highly influenced by the porosity and pore size. The 
wall thickness plays an important role in the equilibrium time (the 
thicker the wall is, the longer it takes for an equilibrium to be reached, 
as the wall decreases the speed of mass transfer between the sample 
matrices and extraction solvent) [63]. Leinonen et al. [30] noticed a 
wide difference among the extraction efficiency of anabolic steroids 
(some analytes were not extracted at all) between LLE and HF-LPME. 
The reason for the difference being the high adsorption of the analytes 
to the PP, and therefore the material of the fiber is another factor that 
should be considered during optimization. One of the studies used a 
polyethersulfone home-made fiber for HF-LPME [54], and the recovery 
results exceeded 90% for all analytes studied. 
2.4.5. Solvent 
Different organic solvents were used to impregnate the fiber and as 
acceptor phase. Most of the solvents are long-chain alcohols (1-heptanol, 
1-octanol, 1-nonanol, and 1-undecanol) due to their ability to not only 
extract most of the analytes via interaction through dispersion forces and 
hydrophobic effect, but also, to increase the ability to interact through 
dipole-dipole or hydrogen-bonding interactions, increasing the extraction 
of more polar analytes [1]. Some solvents with high extractability 
performance are too volatile to be used in a microextraction method. An 
option to overdraw this issue is to use less volatile solvents as co-solvents 
(approach adopted by Sun et al. [48]). Other studies also used a mixture 
of solvents to extract the analytes [24,32,51]. In 2013 [43], a research 
group used so-called supramolecular solvents for HF-LPME extraction for 
the first time, and it proved to be a suitable substitute for organic solvents 
in 2-phase HF-LPME procedures, which also reinforces the green 
chemistry aspect of HF-LPME [12]. Supramolecular solvents are emulsions 
produced by coacervation of water-immiscible liquids dispersed in 
a water-based continuous phase. The study in focus produced the vesicular 
coacervate by mixing a long-chain carboxylic acid (decanoic acid) 
and a quaternary ammonium salt (tetrabutylammonium hydroxide) in 
distilled water. To dissolve the decanoic acid, stirring was applied 
(1200 rpm for 10 min) and the phases were separated by centrifugation. 
From this procedure, a vesicular coacervate solvent was obtained and 
used in the HF-LPME. Due to the presence of the polar regions, consisting 
of protonated and deprotonated carboxylic and ammonium groups, 
many different interactions, including electrostatics, ionic, and hydrogen 
bonds, can be established with analytes besides the usual hydrophobic 
interactions [43]. 
2.4.6. Derivatization 
All studies that used derivatization [26,33,53,54] concluded that intube/ 
in-situ derivatization – where derivatization happens within the 
walls of the fiber during the extraction – can be used instead of the 
traditional derivatization procedure (where derivatization takes place 
in a separate vial). Kramer et al. [26] compared both derivatization 
methods and obtained poorer extraction efficiencies with in-tube derivatization; 
the reason being the mild temperature and short time employed 
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by the authors, who justified the lower performance stating that 
the ease and speed of the method compensates for this decrease. Liu 
et al. [33], on the other hand, obtained better results for in-situ derivatization, 
and one of the reasons could be the longer extraction time 
and higher temperature employed in this study. 
2.4.7. Forced convection 
All 2-phase HF-LPME were performed under forced convection 
(stirring, shaking/vortexing/vibrating, or ultrasonicating). Around 80% 
of the articles used stirring with a magnetic stir bar to force convection 
onto the system. Liu et al. [46] introduced ultrasonication in the extraction 
process aiming to enhance the extraction throughput and 
fasten the extraction time by improving mass transfer. They compared 
the extraction time to achieve the equilibrium using stirring or ultrasonication 
under the same conditions (salt concentration, pH, and 
temperature), and the process using ultrasonication achieved equilibrium 
after 10 min, whilst the system using stirring reached equilibrium 
after 30 min. However, the use of ultrasound irradiation must be 
carefully evaluated due to the possibility of damaging the fiber [32]. 
2.4.8. Extraction time 
Most of the extraction processes were between 10 and 30 min (17 
studies) or 30 to 60 min (16 studies). One study [60] aimed to develop a 
rapid screening test for cocaine and metabolites in urine, therefore 
employing a short extraction time (3 min). On the other hand, some 
studies had a long extraction time (equal or higher than 60 min) aiming 
to achieve exhaustion and avoiding a kinetic method [29,44,47,49]. 
2.4.9. Temperature 
Few studies adopted extraction temperature as an optimizable 
parameter. Most of them performed the extraction at room temperature. 
The definition of room temperature was not described in details in 
most of the studies. Few studies adopted temperature higher than 30 °C 
after optimization [31,33–35,38,39,41,46,53,55]. Most of these studies 
justified the positive effect of temperature on the extraction based on 
kinetics and thermodynamics of mass transfer; only three studies 
[33,35,53] justified the higher extraction efficiencies under higher 
temperature based on the improvement of derivatization and hydrolysis 
efficiencies, respectively. Solvent evaporation and solubilization loss 
due to increased temperature must be taken into account as the loss of 
solvent can have a significant impact in HF-LPME due to the low volume 
of solvent used in the process [1,7,10]. 
2.4.10. Electromembrane extraction (EME) 
Only two 2-phase HF-LPME studies [40,52] used EME. EME was 
first used in 2006, and it is widely employed in 3-phase systems in 
which both the donor and acceptor phases are normally aqueous. The 
solvents must present some important characteristics in EME, such as 
good electrical permittivity and potential to dissolve ionic species. 
Daravani et al. [40] compared the EME of a model analyte in 2- and 3- 
phase HF-LPME, and concluded that the 2-phase HF-LPME proved 
faster and simpler. By using a combination of EME and 2-phase HFLPME, 
they concluded that mainly electrokinetic migration was responsible 
for the extraction, and not simple passive diffusion, as the 
equilibrium was achieved in a short period of time. 
2.4.11. Analytical method 
The analytical instrumentation systems employed for separation 
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and detection or quantification of the analytes were very variable (GC, 
LC, CE and ULC with NPD, PD-HID, FID, UV, MS, MS/MS, FPD, ECD or 
FD). For the 2-phase HF-LPME, GC was the most used technique for 
separation due to the nature of the acceptor phase being organic. Some 
of the studies that used LC or ULC [28,30,53] for separation had 
to dry the extracts and reconstitute them with the appropriate solvent 
before injecting onto the instrument. Others used a small injection 
volume (5 μL or 10 μL) to avoid disturbing the chemical equilibrium 
between the mobile phase and the analyte [31,48,55]. Five studies 
[38,47,49,56] did not adopt any of these approaches, but still obtained 
good results using LC-FD and LC-UV. The study that used supramolecular 
solvent also injected a relatively high volume (20 μL) of extract 
onto the LC-UV [43]. One study [44] took 10 μL of the acceptor phase 
(1-octanol), and diluted with 300 μL of methanol before the injection 
onto the LC. 
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Ref. Analytes Matrix 
Donor phase: 
Volume 
pH 
Additives 
Fiber: 
Material 
Length 
id(mm)xwt(mm)xps(µm) 
Solvent and Additives Acceptor phase and Additives Extraction process Instrumentation 
[23] 
Diazepam 
Prazepam 
U 
P 
1.5mL 
pH 5.5 
PP 
4cm 
0.6x0.2x0.2 
1-octanol 1-octanol 
Vibrating 
1000rpm 
30min 
GC-NPD 
[24] 
Diazepam 
NDMD 
U 
P 
3.5 (U); 3.0mL (P) 
pH 7.5 
No salt added 
PP 
6cm 
0.6x0.2x0.2 
Butyl acetate:1-octanol (1:1 v/v) (U) 
Dihexyl ether:1-octanol (1:3 v/v) (P) 
Butyl acetate:1-octanol (1:1 v/v) 
(U) 
Hexyl ether:1-octanol (1:3 v/v) (P) 
Vibrating 
600rpm 
50min 
GC-NPD 
[25] 
Cocaine 
Cocaethylene 
EMeE 
AEME 
U 
8mL 
pH 10.6 
PP 
6cm 
0.6x0.2x0.2 
Chloroform Chloroform 
Stirring 
1600rpm 
3min 
GC-PDHID 
[26] THC-COOH U 
8mL 
pH 8 
Bu4N
+-HSO4 
PP 
6cm 
0.6x0.2x0.64 
Octane:BSTFA (1:5 v/v) Octane:BSTFA (1:5 v/v) 
Stirring 
1540rpm 
Room T 
8min 
GC-PDHID 
[60] 
Cocaine 
Cocaethylene 
EMeE 
AEME 
OF 
2.2mL 
pH 10.5 
PP 
7cm 
0.6x0.2x0.2 
Chlorophorm Chlorophorm 
Stirring 
2000rpm 
10min 
GC-PDHID 
[27] 
Methadone 
Promethazine 
Haloperidol 
U 
P 
4mL 
pH 13.1 
PP 
8cm 
0.6x0.2x0.2 
Dihexyl ether Dihexyl ether 
Vibrating 
1500rpm 
45min 
GC-FID 
[28] Mirtazapine P 
4mL 
pH 13.6 
No salt added 
PP 
7cm 
0.6x0.2x0.2 
Toluene Toluene 
Stirring 
30min 
ca. 22oC 
LC-UV 
[29] Basic drugs P pH 7 
PP 
6.5cm 
0.6x0.2x0.2 
1-octanol 1-octanol 
Vibrating 
1500rpm 
60min 
CE-UV 
[30] Anabolic steroids U 
4mL 
pH 7 
No salt added 
PP 
6cm 
0.6xn.r.x0.2 
1-octanol 1-octanol 
Stirring 
1250rpm 
Room T 
45min 
LC-MS 
[31] 
Thiazide diuretics 
Clopamide 
Probenecid 
Loop diuretics 
U 
7.5mL 
pH 2 
15% (w/v) NaCl 
PP 
8cm 
0.6x0.2x0.2 
1-octanol 1-octanol 
Stirring 
1010rpm 
40oC 
40min 
LC-MS/MS 
[32] Flunitrazepam 
P 
U 
4mL 
pH 9.5 (U); 8.0 (P) 
No salt added 
PVDF 
1.8cm 
1.2x0.2x0.2 
p-xylene (U) 
p-xylene:1-octanol (3:7 v/v) (P) 
p-xylene (U) 
p-xylene/1-octanol (3:7 v/v) (P) 
Stirring 
375 (P); 450 (U) rpm 
30oC 
30min 
GC-MS/MS 
[33] 
Clenbuterol 
Metoprolol 
Propranolol 
U 
5mL 
pH 12 
14% (w/v) NaCl 
PP 
1.6cm 
0.6x0.2x0.2 
Methylbenzol Methylbenzol:MSTFA (1:1 v/v) 
Stirring 
925rpm 
35oC 
20min 
GC-MS 
[54] Free cyanide 
U 
OF 
5mL 
pH 6.5 
Saturated with 
Na2SO4 
Polyethersulfone 
1.5cm 
3.75x0.75x0.2 
Sodium carbonate + Ni(II)-NH3 
Sodium carbonate + Ni(II)-NH3 
pH 11 
Stirring 
900rpm 
Room T 
10min 
CE-UV 
[61] 
THC 
CBD 
H 
10mg 
pH 14 
PP 
6cm 
Butyl acetate Butyl acetate 
Stirring 
600rpm 
GC-MS/MS 
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CBN 6.8% (w/v) NaCl 0.6x0.2x0.2 Room T 
20min 
[34] 
Promethazine 
Promazine 
Chlorpromazine 
Trifluoperazine 
U 
3mL 
pH 9 
No salt added 
PP 
1.5cm 
0.6x0.2x0.2 
Toluene Toluene 
Stirring 
1000rpm 
40oC 
10min 
GC-FPD 
GC-FID 
[5] 
Amphetamines 
Caffeine 
Ketamine 
U 
3mL 
pH 12.5 
30% (w/v) NaCl 
PP 
1cm 
0.6x0.2x0.2 
o-xylene o-xylene 
Stirring 
1000rpm 
Room T (30oC) 
20min 
GC-FID 
[35] 
Pyrethroid 
metabolites 
U 
5mL 
pH ca. 1 
PP 
1.5, 2.0, 2.5 and 3.0cm 
0.6x0.2x0.2 
1-octanol 1-octanol 
Stirring 
70oC 
10min 
GC-ECD 
[36] 
Alfentanil 
Fentanyl 
Sufentanil 
P 
U 
3mL 
pH ca. 11 
No salt added 
PP 
1cm 
0.6x0.2x0.2 
Dihexyl acetate Dihexyl acetate 
Stirring 
1000rpm 
Room T (25oC) 
15min 
GC-NPD 
[59] 
Amitriptyline 
Imipramine 
Promethazine 
B 
30µL 
pH 11 
No salt added 
PP 
1cm 
0.6x0.2x0.2 
Toluene Toluene 
Stirring 
Room T 
10min 
GC-MS 
[37] Tramadol 
P 
U 
12mL 
pH 12 
No salt added 
PP 
1.5cm 
n.r. 
1-nonanol 1-nonanol 
Stirring 
1000rpm 
Room T 
25min 
GC-MS 
[38] Guaifenesin P 
25mL 
pH 7.4 
1.7% (w/v) K2HPO4 
PP 
8cm 
0.6x0.2x0.2 
1-octanol 1-octanol 
Stirring 
600rpm 
37oC 
30min 
LC-FD 
[39] Anabolic steroids 
U 
H 
20mL 
No pH adjustment 
7.5% (w/v) NaCl 
PP 
1.2cm 
1.8x0.2x0.2 
Toluene Toluene 
Stirring 
750rpm 
40oC 
30min 
GC-MS 
[40] 
Imipramine 
Desipramine 
Citalopram 
Sertraline 
U 
1.2mL 
Neutral (pH ca. 7) 
PP 
2.2cm 
0.6x0.2x0.2 
1-heptanol 1-heptanol 
Stirring 
1400rpm 
60V 
15min 
GC-MS 
[41] 
Sulfetanil 
Alfentanil 
P 
U 
5mL 
pH 10 
15% (w/v) NaCl  
PP 
1.3cm 
0.6x0.2x0.2 
1-octanol 1-octanol 
Stirring 
700rpm 
50oC 
25min 
GC-FID 
[42] 
Fluoxetine 
Norfluoxetine 
P 
5mL 
pH 11 
No salt added 
PP 
3.7cm 
0.6x0.2x0.2 
Dihexyl ether Dihexyl ether 
Vibrating 
700rpm 
30min 
GC-MS 
[43] Benzodiazepines 
P 
U 
ca. 5 (P); ca. 25 (U) 
mL 
pH ca. 9 
No salt added 
PP 
10cm 
0.6x0.2x0.2 
Supramolecular solvent Supramolecular solvent 
Stirring 
900rpm 
50min 
LC-UV 
[44] 
Indomethacin 
Dexamethasone 
Propafenone 
P 
U 
1.8ml 
pH 2, 2-8, 10 
20% (w/v) NaCl 
PVDF 
3.5cm 
n.r.xn.r.xn.r. 
1-octanol 1-octanol 
Vibrating 
173rpm 
Room T 
102, 120 and 102min 
LC-UV 
[45] Methadone 
P 
U 
10mL 
pH 11.5 
PP 
2cm 
1-undecanol 1-undecanol 
Stirring 
700rpm 
GC-FID 
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5% (w/v) NaCl 0.6x0.2x0.2 20oC 
45min 
[46] Nicotine P 
4.5mL 
pH 7.4 
29% (w/v) NaCl 
n.r. 
3cm 
n.r. 
1-octanol 1-octanol 
Sonicating 
37oC 
10min 
GC-FID 
[47] Amlodipine U 
24mL 
pH 10 
1.2% (w/v) NaCl  
PP 
8.5cm 
0.6x0.2x0.2 
1-octanol 1-octanol 
Stirring 
1000rpm 
60min 
LC-UV 
[48] 
Naloxone 
Buprenorphine 
Norbuprenorphine 
P 
5mL 
pH 8.7 
No salt added 
PVDF 
4cm 
0.8x0.175x0.16 
1-octanol:chlorophorm:toluene  
(2:4:4 v/v/v) 
1-octanol:chlorophorm:toluene 
(2:4:4 v/v/v) 
Stirring 
1000rpm 
20oC 
30min 
ULC-MS 
[49] Hydrochlorothiazide U 
24mL 
pH 12 
No salt added 
PP 
8.5cm 
0.6x0.2x0.2 
1-octanol  + 2% (w/v) Aliquat 336 1-octanol  + 2% (w/v) Aliquat 336 
Stirring 
800rpm 
90min 
LC-UV 
[50] 
Amphetamines 
Methcatinone 
Ketamine 
Meperidine 
Methadone 
U 
B 
8mL 
pH 13 
PP 
4cm 
0.6x0.2x0.2 
Toluene Toluene 
Stirring 
500rpm 
30oC 
15min 
GC-MS 
[51] Flunitrazepam 
P 
U 
4mL 
pH 9.5 (U); 8.0 (P) 
No salt added 
PVDF 
1.8cm 
1.2x0.2x0.2 
p-xylene (U) 
p-xylene:1-octanol (3:7 v/v) (P) 
p-xylene (U) 
p-xylene:1-octanol (3:7 v/v) (P) 
Stirring 
375 (P); 450 (U) rpm 
30oC 
30min 
GC-MS 
[52] Metamphetamine 
H 
U 
4mL 
pH 7 
No salt added 
PP 
6cm 
0.6x0.2x0.2 
1-octanol + 2.5mg/mL grapheme oxide 1-octanol 
Stirring 
1000rpm 
60V 
20min 
GC-FID 
[53] Memantine P 
10mL 
pH 13 
No salt added 
PP 
8cm 
0.6x0.2x0.2 
Cyclohexane 
Cyclohexane + 0.3mg/mL dansyl 
chloride + 4% (v/v) triethylamine + 
10% (v/v) acetone 
Stirring 
800rpm 
40oC 
50min 
LC-FD 
[55] 
Naproxen 
Nabumetone 
P 
U 
pH 3 
KCl 4% (w/v) 
PP 
4cm 
0.6x0.2x0.2 
1-undecanol 1-undecanol 
Stirring 
600rpm 
45oC 
20min 
LC-FD 
[56] 
Albendazole 
Triclabendazole 
U 
pH 8 
No salt added 
PP 
8.8cm 
0.6x0.2x0.2 
1-undecanol 1-undecanol 
Vortexing 
Room T 
3min 
LC-FD 
[58] 
Oxazepam 
Lorazepam 
U 
P 
25mL 
No pH adjustment 
7.5% (w/v) NaCl 
PP 
10cm 
0.6x0.2x0.2 
1-octanol 1-octanol 
Stirring 
1000rpm 
50min 
LC-MS 
[49] HCTZ U 
24mL 
pH 12  
No salt added 
PP 
8.5cm 
0.6x0.2x0.2 
1-octanol + Aliquat 336 2% (w/w) 
 
1-octanol + Aliquat 336 2% (w/w) 
 
Stirring 
800rpm 
90min 
LC-UV 
[57] Warfarin P 
8mL 
pH 6.5 
No salt added 
PP 
3cm 
0.6x0.2x0.2 
1-octanol + CTAB 10mM 1-octanol + CTAB 10mM 
Stirring 
800rpm 
Room T 
25min 
UV-Vis 
 
Table 2. 2-phase HF-LPME (conventional and variants) of drugs of forensic interest in biological matrices. The concentration values of salt added were converted 
to % (w/v); the pH were calculated based on the concentration of base or acid in some cases. Abbreviations: (A) = acidic; AEME = anhydroecgonine methyl 
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ester; Aliquat-336 = 3-caprylil methyl ammonium chloride; (B) = basic; B = whole blood; BSTFA = bis(trimethylsilyl)trifluoroacetamide; Bu4N+-HSO4= tetra-n-
butylammonium; ca. = approximately; CBD = cannabidiol; CBN = cannabinol; CE = capillary electrophoresis; ECD = electron capture detector; EMeE = ecgonine 
methyl ester; FD = fluorescent detector; FID = flame ionization detector; FPD = flame photometric detector; GC = gas chromatography; H = hair; id = internal 
diameter; K2HPO4 = dipotassium phosphate; LC = high performance liquid chromatography; MS = mass spectrometry; MS/MS = tandem mass spectrometry; 
n.r. = not reported; Na2SO4 = sodium sulfate; NaCl = sodium chloride; NDMD = N-desmethyldiazepam; NPD = nitrogen-phosphorus detector; OF = oral fluid; P 
= plasma; PDHID = pulsed-discharge helium ionization detector-helium ionization detector; PP = polypropylene; ps = pore size; PVDF = polyvinylidene difluoride; 
T = temperature; THC-COOH = 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid; THC = Δ9-tetrahydrocannabinol; wt = wall thickness; U = urine; ULC = ultra-
high performance liquid chromatography; UV = ultra-violet 
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2.5. Three-phase HF-LPME 
One hundred and forty-two bioanalytical methods were described in 
136 publications fit the inclusion criteria (Table 3) for 3-phase HFLPME. 
2.5.1. Biological matrices 
Similarly to 2-phase HF-LPME, most of the 3-phase HF-LPME 
methods included in the systematic review used plasma (92 out of 142) 
and/or urine (99 out of 142) as the matrix. Few methods used other 
matrices, such as whole blood [64–71], breast milk [72–74], serum 
[75,76], oral fluid [77,78], hair [79], or liver [80]. 
Halvorsen et al. [64] demonstrated that despite the complexity of 
whole blood as a matrix the recoveries obtained for whole blood and 
plasma were similar during the extraction of methamphetamine and 
citalopram. However, the time to reach the equilibrium was twice as 
long for whole blood. The same group [65] of researchers tested a 
screening test for amphetamines, and the LOD observed for urine were 
higher than the LOD observed for whole blood due to the high noise 
from urine samples. They [66] also qualitatively evaluated matrix effects 
using the HF-LPME combined with LC-MS for plasma and whole 
blood, and no ion suppression was observed due to the effective sample 
clean-up by HF-LPME. Indeed the HF-LPME provided a good clean-up 
for whole blood without requiring any complex pre-treatment in all the 
included studies. Gjelstad et al. [68] showed that the dilution of whole 
blood per se tends to improve the efficiency of the process, making the 
recovery of basic drugs similar to their recovery from plasma. All of the 
studies used simple dilution to deal with whole blood samples. 
Low recoveries (18–38%) previous to any pre-treatment were obtained 
for breast milk [72], and the authors believe this is due to the 
rate of drug binding to the sample matrix. The authors tested different 
pre-treatments, and after centrifugation or acidification followed by 
centrifugation the recoveries improved, reaching up to 69%. By using 
EME, Kjelsen et al. [73] obtained good recoveries from breast milk 
(comparable to the recoveries obtained from plasma and urine). The 
recoveries of levimasole using oral fluid as the biological matrix were 
similar to those obtained from other matrices [78] using EME. Comparable 
recoveries were also obtained for lidocaine and chlorpromazine 
from serum and urine in two studies [75,76]. 
One study used hair to analyse amphetamine-type stimulants [79] 
whilst another study [80] used liver samples to analyse barbiturates, 
and due to the complexity of dealing with these matrices, the sample 
preparation is more complex and is detailed in the articles. 
2.5.2. Ionic strength 
From the 136 studies, 51 did not optimize ionic strength. Sixty out 
of the 142 methods [56,62,75,77,78,81–134] decided not to use salt 
after optimization (some studies included more than one method, 
therefore the number of references can differ from the number of 
methods), and 27 used sodium chloride with concentrations ranging  
between 1% to around 30% (w/v). One study used potassium chloride 
for salting-out effect, and 3 studies [54,135,136] used sodium sulfate at 
different concentrations. Two studies compared sodium sulfate to different 
salts; Lv et al. [135] compared sodium chloride and sodium 
sulfate at the same concentrations, and the sulphate presented better 
results. However, as the ionic strength is related to the concentration of 
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all the ions in solution, sodium sulfate is ionically stronger when in 
solution, and comparing both salts in the same concentration is not the 
same as comparing their ionic strength. Moreover, this study used a 
carrier and the decreased interaction between the elements of the 
biological sample and the carrier by the use of a salt could be the reason 
for the increase in extraction efficiency. 
2.5.3. Ion pairing 
The use of ion-pairing agents was present in only 28 methods (27 
studies) of the 142 methods [29,58,77,78,82,83,85,99,100,106,111, 
120,126,132,133,135,137–147]. Aiming to correlate solubility and 
distribution coefficient (log D) data with extraction recoveries, Pedersen- 
Bjergaard et al. [29] assessed different HF-LPME methods (2- 
phase HF-LPME and 3-phase HF-LPME with and without carrier) to 
extract drugs with dissimilar chemical behaviour. They found that for 
those drugs with water solubility values above 150 mg/mL and log 
D < 1.8 at pH 13, carrier-mediated HF-LPME should be the preferred 
technique. The same research group performed other studies using 
carrier agents. One of these studies [138] compared different organic 
borates, phosphates, sulfates, and carboxylic acids as pairing agents to 
extract hydrophilic basic drugs. Carriers tested were both water soluble 
and not, and therefore, some carriers were solubilized in the donor 
phase and some of them in the solvent. An important conclusion of this 
study is the demonstration of non-compatibility of some carriers with 
biological samples due to the precipitation of proteins on the surface of 
the fibers and in the donor phase. They also showed that by saturating 
the biological sample with sodium sulfate it is possible to increase the 
recoveries using a carrier due to the suppression of the interactions 
between the carrier and plasma proteins that this agent provides. Aliquat- 
336 was used in approximately one fifth of the 3-phase HF-LPME 
studies that used a carrier agent (6 out of 28), and 10 studies used 
TEHP, DEHP or both. Combination with EME was used in some studies 
[77,78,85,106,120,126,141,144,147]. A recent study [85] used C60 
fullerene as a carrier agent for the first time. It compared the proposed 
EME procedure using C60 fullerene as a modifier to conventional EME 
and showed that the carbon nanostructured material increased the 
method recovery by 30% and decreased its LOD by around 8 times. 
2.5.4. Fiber 
Most of the articles that described the fibers used in the extraction 
procedure used the traditional PP fibers previously cited; some articles 
that used PP fibers with other dimensions [29,64,66–68,72–74,110, 
131,134,148–154] or fibers made of different material, such as PVDF 
[109]. Xi et al. [151] compared fibers made of different materials (PP, 
PVDF, polysulfone, and polyethersulfone) and with different dimensions. 
The PP fiber with 0.45mm wall thickness and 0.18 μm pore size 
presented the best results. Without any further information about 
porosity percentage and wall thickness of the PVDF, polysulfone and 
polyethersulfone fibers, it is not possible to properly correlate the best 
performance of the PP fiber to its dimensions and composition. Halvorsen 
et al. [64] showed that by changing the dimensional parameters 
of the hollow fibers it is possible to obtain a considerably shorter 
equilibrium time, mainly when complex biological matrices are used. 
This happens when the contact area is increased and the wall thickness 
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is reduced. As expected, the differences between the recoveries were 
not significant after the equilibrium was reached. 
2.5.5. Solvent 
The most common solvent used to impregnate the hollow fiber was 
1-octanol (49 studies), followed by dihexyl ether (28), NPOE (20), and 
aliphatic hydrocarbons (16). Other solvents consisted of other longchain 
aliphatic alcohols, esthers, silicon oil, etc. Some studies aimed to 
develop green bioanalytical methods by testing essential and fixed oils 
from plants. Four studies [80,138,149,155] used plant oils in their 
extraction method and obtained good results, and this reinforces the 
idea of the green chemistry already at the core of the concept of HFLPME. 
One of the studies [149] tested different fixed (almond, arachis, 
olive, and soy-bean) and essential (anise, fennel, lavender, and peppermint) 
oils and compared with traditional HF-LPME solvents (dihexyl 
ether, 1-octanol, and dodecyl acetate) to extract the same group of 
analytes; the results were similar between the essential oils and the 
traditional HF-LPME solvents. The fatty oils presented worse results 
probably due to their high viscosity, which lowers the diffusion rate 
across the organic phase. It was not possible to immobilize eucalyptus, 
lemon, tea tree, clove, and thyme oil, and also oil of turpentine in the 
walls of the fiber. Ho et al. [138] compared the carrier-mediated extraction 
of 8 drugs from plasma using peppermint oil or conventional 
solvents (1-octanol, dihexyl ether, NPOE, 2-octanone, dodecyl acetate, 
and silicon oil AR20); seven out of 8 drugs had higher extractions using 
peppermint oil. Menck et al. [80] also tested different fixed and essential 
oils to extract barbiturates from liver samples, and even though 
eucalyptus oil did not present the best results for all the analytes, it was 
adopted as the best option due to its good performance. Eucalyptus oil 
was also chosen as the best option for extracting ketamine and its 
metabolites from urine in other study [155]. 
2.5.6. Derivatization 
Four studies used in-situ derivatization during the 3-phase HF-LPME 
[30,95,122,129]. Derivatization played different roles in the included 
studies: it was used to make a compound susceptible to analysis using 
GC by increasing its volatility [30], to create a chromophore making the 
compound possible to be analysed by UV [95], or just to make the 
compound less hydrophilic to facilitate its migration to the solvent 
[122,129]. Also the derivatization took place in different places in the 
system: in the fiber [30], in the donor phase during the extraction 
[122,129], or in the donor phase prior to extraction [95]. The adoption 
of harsher conditions (45 °C for 30 min) employed by Leinonen et al. 
during the extraction is based on the need of this condition for derivatization. 
Relatively low recoveries were obtained in this study due to 
the sensitivity of sylilation to the water present in the sample; the authors 
tried to overdraw this by using dihexyl ether as the solvent layer 
membrane to protect the reaction that happened in the lumen of the 
fiber. 
2.5.7. Forced convection 
Most of the methods used stirring (104 out of 142) or vibration/ 
vortexing/shaking (25 out of 142) to force the convection of the system. 
Three studies used sonication for this purpose [69,80,156]. Four 
studies did not provide the system with any agitation method 
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[70,150,151,157]. Eibak et al. and Jamt et al. tried to simplify the 
extraction method by not stirring the system; Xi et al. did not use any 
convection method to avoid influencing the drug-protein binding. One 
study used magnetofluid to stir the system [158], and that provided the 
method with shorter extraction time (8 min). No study directly compared 
different agitation methods, and this is a potential field to be 
explored by future researchers. 
2.5.8. Extraction time 
Regarding the extraction duration, some studies presented short 
extraction time (equal to or<5 min) [56,70,73,110,150]. Apart from 
one study [56], all of them employed EME, which explains why the 
methods were shorter. Even though two other studies [69,80] presented 
relatively short extraction times (5 min), time was not an optimized 
parameter; these studies used ultrasonication as a forced convection 
method. Eibak et al. [150] presented for the first time an EME kinetic 
method, which effectively quantified amitriptyline, citalopram, 
fluoxetine, and fluvoxamine in human plasma within 1 min. Song et al. 
[158] developed and validated a method to quantify aristolochic acids 
in human plasma and, according to the authors, the short extraction 
time (8 min) was due to the use of magnetofluid during the magnetic 
stirring of the samples. Eskandari et al. [102] showed a significant 
decrease in extraction time (from 60 to 15 min) by adopting EME instead 
of the conventional HF-LPME. Other studies also compared EME 
to HF-LPME [102,141,157]. 
On the other hand, some studies presented a long extraction time 
(equal to or>60 min, reaching up to 5 h) after optimizing this parameter 
[47,49,67,83,90,98,100,102,116,131,143,151,153,154,159–161]; 
other studies adopted long extraction times but did not optimize this 
[29,72,138,139]. Halvorsen et al. [64] showed that by increasing the 
contact surface between the solvent impregnated within the fiber walls 
and the donor and acceptor phases it is possible to decrease the extraction 
time (in this case, by a factor of 2). Xi et al. [151] adopted a 5- 
hour extraction method due to the stagnant characteristic of the system 
(the aim of the study was to determine the protein-binding properties of 
the drugs). According to the central composite design by Ebrahimzadeh 
et al. [162] the extraction time did not play an important role in the 
method, however, a long extraction time was adopted to ensure equilibrium 
was reached. One study presented a total extraction time of 
60 min [129] but it was a sequential extraction of two drugs with different 
systems in the same vial. Some studies justified the long extraction 
time based on the complex nature of the biological matrices 
[64,67]. 
2.5.9. Temperature 
Temperature was optimized in 12 methods [30,71,86,97,104, 
109,122,163], [160,164–166]. Two of them [30,122] explained the use 
of higher temperatures to perform rapid and higher derivatization. The 
general behaviour of the extraction with increasing temperature was 
the increase of the extraction efficiency, and after achieving an optimum 
temperature, the decrease of the efficiency. The main reasons for 
this could be solvent depletion (due to easier solubilization of the solvent 
in the donor phase at higher temperatures, or due to volatilization), 
and fiber damaging. An important factor to be considered is the 
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Joule effect that can happen during the EME, which can increase the 
temperature of the system [1]. 
2.5.10. Electromembrane extraction 
Thirty-one methods used EME to perform their extractions 
[68,70,73,77,78,85,102,106,107,110,112,120,121,124,126,131,132, 
134,141,142,144,147,150,157,167–171]. From those, 20 used NPOE as 
the extraction solvent (with or without a carrier), and according to 
authors this solvent is already well established as a good option for EME 
for extracting basic compounds; 1-octanol, a traditional solvent for HFLPME 
is less likely to be used with EME due to the formation of bubbles 
under high voltage [110]. One of the advantages of using EME is that it 
usually does not require sample pre-treatment [68,70,120,150,157]. 
Some studies showed that the kinetics of the EME can be slower when 
applied to biological matrices, potentially leading to a lower recovery 
after the same extraction time [68,73,141,157,167]; this is probably 
due to protein binding and higher viscosity of the biological samples. 
The performance of EME was compared to the performance of conventional 
HF-LPME in some studies [102,131,141,157,167], and EME 
proved to be faster and more efficient in general. EME showed to be 
effective even for stagnant systems and short extraction times 
[150,157]. Daravani et al. [110] were the first to try to extract acidic 
compounds from complex biological matrices using EME. After this 
study other studies included acidic compounds, one of them [120] 
using 2 fibers in the same system to extract basic and acidic substances 
simultaneously. For that Seidi et al. impregnated the different fibers 
with different solvents that presented optimum extraction for both 
types of drugs. Other studies compared sequential and simultaneous 
extraction of acidic and basic substances, and the sequential option 
presented better performance [74]. Koruni et al. [126] also used different 
fibers and different systems to extract acidic and basic drugs with 
a wide range of partition coefficients (log P), and for this four systems 
were used for simultaneous extraction. Koruni et al. [126] adopted an 
interesting approach to analyse basic and acidic compounds simultaneously 
by using a set of two auxiliary electrodes and hollow fibers. 
Eibak et al. [157] used multiple fibers, however, the aim was not to 
simultaneously extract drugs with different properties but to demonstrate 
how an increase in the supported liquid membrane (SLM) contact 
area and acceptor phase volume could impact the extraction efficiency. 
The objective of the study was to achieve exhaustive extraction (recoveries> 
95%) in a short period of time by this geometry optimization 
of the HF-LPME system, and also to test different extraction procedures 
(by changing volume of donor phase and convection process). 
Even though they succeeded in achieving an exhaustive extraction from 
water, the same was not observed when extracting from plasma, most 
likely due to protein binding. Moreover, even using the 3-fiber system, 
only one out of six drugs were exhaustively extracted after 45 min when 
a pH difference was used as the driving force rather than a voltage 
difference, i. e., conventional HF-LPME instead of EME. On the other 
hand, all the drugs were exhaustively extracted after 10 min when EME 
was employed. 
2.5.11. Analytical method 
A wide range of analytical systems were employed for separation, 
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detection and/or quantification of analytes extracted using 3-phase HFLPME. 
Differently from 2-phase HF-LPME, GC was used less frequently, 
and LC and CE were employed more, again due to the aqueous nature of 
the acceptor phase used in this type of HF-LPME. Some studies were 
classified as 3-phase HF-LPME for presenting an acceptor phase different 
from the solvent within the walls of the fiber even though both 
are organic solvents [58,62,86,119,133,145,172,173]. Daravani et al. 
[168] injected the aqueous extract directly into the GC; according to the 
authors the water phase does not damage bonded and cross-linked 
nonpolar stationary phases, but a strong acid or base does. For that 
reason neutralization of the pH 2 aqueous extract by potassium hydroxide 
(KOH) was performed and glass wool was placed in the injector 
line to prevent non-volatile compounds originating from the neutralization 
reaction to reach the column. Some other studies 
[69,71,79,80,155,174] dried the aqueous extract before reconstituting 
with an organic solvent prior to injection directly into the instrument. 
All the studies that dried the samples and reconstituted them in organic 
solvent used derivatization in this process, except one [71]. 
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Ref.     Analytes 
Matri
x 
Donor phase 
Fiber: 
Material 
Length 
id(mm)xwt(mm)xps(µm
) 
Solvent and Additives 
Acceptor phase and 
Additives 
Extraction process Instrumentation 
[87] Methamphetamine 
U 
P 
2.5mL 
pH 13 
No salt added 
PP 
8cm 
0.6x0.2x0.2 
1-octanol 
HCl 0.1M 
pH 1 
Stirring 
400rpm 
45min 
CE-UV 
[175] 
Ibuprofen 
Naproxen 
Ketoprofen 
U 
2.5mL 
pH 1 
PP 
8cm 
0.6x0.2x0.2 
Dihexyl ether 
NaOH 0.01mM 
pH 12 
Vibrating 
400rpm 
45min 
CE-UV 
[23] 
Metamphetamine 
(CE) 
Naproxen (CE) 
Citalopram (LC) 
NDCIT (LC) 
U 
P 
1-4mL 
Variable pH 
PP 
4 or 8cm 
0.6x0.2x0.2 
1-octanol 
HCl 0.1M (CE) 
pH 1;  
NaOH 0.02M (LC) 
pH 12.3 
Vibrating 
1000rpm 
45min 
CE-UV 
LC-FD 
[159] 
Citalopram 
NDCIT 
P 
4mL 
pH ca.13 
PP 
8cm 
0.6x0.2x0.2 
Dihexyl ether 
Phosphate buffer 20mM 
pH 2.75 
Vibrating 
1200rpm 
60min 
CE-UV 
[64] 
Methamphetamine 
Citalopram 
U 
P 
B 
4mL 
pH ca.13 
PP 
8cm 
0.6x0.2x0.2 
27cm 
0.33x0.15x0.4 
Dihexyl ether 
HCl 0.1M 
pH 1 
Vibrating 
1500rpm 
15min (U, P); 30min (B) 
CE-UV 
[65] Amphetamines 
B 
U 
1 (B); 4 (U)mL 
pH ca. 13 
PP 
8cm 
0.6x0.2x0.2 
Dihexyl ether 
HCl 0.01M 
pH 2 
Vibrating 
1500rpm 
15min 
FIA-MS/MS 
[176] Mianserin P 
1mL 
pH ca. 13.5 
PP 
8cm 
0.6x0.2x0.2 
Dihexyl ether 
HCl 0.01M 
pH 2 
Vibrating 
1500rpm 
45min 
CE-UV 
[27] 
Methadone 
Promethazine 
Haloperidol 
U 
P 
4mL 
pH 13.1 
PP 
8cm 
0.6x0.2x0.2 
Dihexyl ether HCl 10mM 
Vibrating 
1500rpm 
45min 
CE-UV 
[148] 
Citalopram 
Desmethylcitalopram 
P 
1.5mL 
pH ca. 13 
PP 
1.8cm 
1.2x0.2x0.2 
Dodecyl acetate 
Phosphate 20mM 
pH 2.75 
Vibrating 
1500rpm 
45min 
CE-UV 
[72] 
Paroxetine 
Fluvoxamine 
Mianserin 
Citalopram 
M 
1.5mL 
pH ca. 13.5 
PP 
1.8cm 
1.2x0.2x0.2 
Polyphenyl-methylsiloxane 
HCl 10mM 
pH 2 
Vibrating 
1500rpm 
60min 
CE-UV 
[66] 
Antidepressant drugs  
(TCA and SSRI) 
P 
B 
1.5mL 
pH 13.1 
PP 
1.8cm 
1.2x0.2x0.2 
Dodecyl acetate 
Formic acid 200mM 
pH ca. 2 
Vibrating 
 1500rpm 
30min 
LC-MS 
CE-UV 
[137] 
Amphetamine 
Morphine 
Practolol 
P 
U 
4mL 
pH 7 
Sodium octanoate 
PP 
8.0cm 
0.6x0.2x0.2 
1-octanol 
HCl 50mM 
pH 1.3 
Vibrating 
1500rpm 
45min 
CE-UV 
[67] 
Zolpidem 
Benzodiazepines 
B 
1.5mL 
pH 7.5 
PP 
1.8cm 
1.2x0.2x0.2 
Nonanol 
HCl 0.4M 
pH 0.4 
Vibrating 
1500rpm 
60min 
LC-UV 
LC-MS 
[149] 
Amphetamines 
Pethidine 
Nortriptyline 
Methadone 
P 
U 
1mL 
pH ca. 13.5 
PP 
1.8cm 
1.2x0.2x0.2 
Plant fatty oils 
Plant essential oils 
Formic acid 10mM 
pH 2.9 
Vibrating 
1200rpm 
45min 
CE-UV 
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Haloperidol 
Loperamide 
[139] 
Amphetamine 
Phenylpropanolamin
e 
Cimetidine 
Morphine 
β-blockers 
P 
0.1mL 
pH 7 
Sodium octanoate 
PP 
6.5cm 
0.6x0.2x0.2 
1-octanol 
HCl 50mM 
pH 1.3 
Vibrating 
1500rpm 
60min 
LC-MS 
[29] Basic drugs P 
1.5mL 
pH 13 
Sodium octanoate 
PP 
1.8cm 
1.2x0.2x0.2 
Dodecyl acetate 
HCl 10mM 
pH 2 
Vibrating 
1500rpm 
60min 
CE-UV 
[138] 
Amphetamine 
Phenylpropanolamin
e 
Metaraminol 
Cimetidine 
Morphine 
β-blockers  
P 
0.1mL 
pH 7 
Bromothymol blue 
PP 
6.5cm 
0.6x0.2x0.2 
1-octanol or peppermint oil 
HCl 50mM 
pH 1.3 
Vibrating 
1500rpm 
60min 
CE-UV 
[30] Steroids metabolite U n.r. n.r. Dihexyl ether 
MSTFA:ammonium 
iodide:dithioerythritol 
(1000:2:4, v/m/m) 
Stirring 
1250rpm 
45oC 
30min 
GC-MS 
[177] 
Imipramine 
Amitriptyline 
Setraline 
P 
U 
11mL 
pH 12 
PP 
8.8cm 
0.6x0.2x0.2 
1-dodecane 
H3PO4 0.1M 
pH 2.1 
Stirring 
700rpm 
30min 
LC-UV 
[88] Clenbuterol U 
7.5mL 
pH 14 
No salt added 
PP 
4.5cm 
0.6x0.2x0.2 
1-octanol 
Formic acid 5M 
pH 1.5 
Stirring 
1000rpm 
30min 
LC-UV 
LC-MS/MS 
[178] 
Hydroxychloroquine 
and metabolites 
U 
ca. 4.3mL 
pH ca.13 
10% (w/v) NaCl 
PP 
7cm 
0.6x0.2x0.2 
1-octanol 
HCl 100mM 
pH 1 
Stirring 
1200rpm 
Room temperature (ca. 
22oC) 
40min 
CE-UV 
[75] Chlorpromazine 
U 
Se 
11mL 
pH 11.8 
No salt added 
PP 
8.8cm 
0.6x0.2x0.2 
1-dodecane 
HCl 0.01M 
pH 2 
Stirring 
1000rpm 
Room temperature 
20min 
LC-UV 
[89] 
Strychnine 
Brucine 
U 
4mL 
pH ca.13.5 
No salt added 
PP 
8cm 
0.6x0.2x0.2 
1-octanol 
H3PO4 100mM 
pH 1.6 
Stirring 
1500rpm 
Room temperature 
40min 
CE-UV 
[90] 
Tetradrine 
Fangchinoline 
P 
4.5mL 
pH 8.5 
No salt added 
PP 
7.5cm 
0.6x0.2x0.2 
1-octanol 
HCl 5mM 
pH 2.3 
Stirring 
1100rpm 
Room temperature (ca. 
22oC) 
60 min 
LC-UV 
[156] 
Mirtazapine and 
metabolites 
P 
4mL 
pH 8 
15% (w/v) NaCl 
PP 
8cm 
0.6x0.2x0.2 
Dihexyl ether 
Acetic acid 0.01M 
pH 3.4 
Sonicating 
ca. 35oC 
45min 
LC-MS 
[91] 
Mefloquine 
Carboxymefloquine 
P 
4mL 
pH ca.13.5 
No salt added 
PP 
6.5cm 
0.6x0.2x0.2 
Dihexyl ether 
HClO4 10mM 
pH 2 
Stirring 
1100rpm 
Room temperature (ca. 
23oC) 
LC-UV 
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30 min 
[92] 
Chloroquine and 
metabolites 
P 
4mL 
pH 11 
No salt added 
PP 
7cm 
0.6x0.2x0.2 
1-octanol TFA 0.1M 
Stirring 
1200rpm 
Room temperature (ca. 
23oC) 
30min 
LC-MS/MS 
[73] 
Pethidine 
Nortriptyline 
Methadone 
Haloperidol 
Loperamide 
P 
U 
M 
1mL 
pH 2 
PP 
2.5cm 
1.2x0.2x0.2 
1-isopropyl-4-nitrobenzene pH 2 
Vibrating 
1000rpm 
10V 
5min 
CE-UV 
[179] TCA P 
1mL 
pH 10 
PP 
3.5cm 
0.6x0.2x0.2 
Dihexyl Ether 
Sodium phosphate 
buffer 50mM 
pH 3 
Stirring 
400rpm 
45min 
CE-UV 
[93] 
Furosemide 
Bumetanide 
Triamterene 
U 
6mL 
pH 1.5 (for acidic) 
pH 12.5 (for basic) 
No salt added 
PP 
0.6x0.2x0.2 
1-octanol 
0.12M NaOH (for acidic) 
pH 13.1 
0.04M H3PO4 (for basic) 
pH 1.9 
Stirring 
250rpm 
Room temperature (ca. 
27oC) 
50min 
LC-UV 
[91] 
Mefloquine 
Carboxymefloquine 
P 
4mL 
pH ca. 12 then pH 
ca. 3 
PP 
15cm 
0.6x0.2x0.2 
Dihexyl ether 
0.01M perchloric acid 
then 0.05M NaOH 
pH 2 and 12.7 
Vibrating 
1750rpm 
30min 
LC-UV 
[68] 
Pethidine 
Nortriptyline 
Tramadol 
Methadone 
Haloperidol 
Loperamide 
P 
B 
0.5mL 
PP 
2.5cm 
1.2x0.2x0.2 
1-ethyl-2-nitrobenzene HCl 10mM 
Vibrating 
1050rpm 
10V 
10min 
CE-UV 
[180] Ibuprofen U 
50mL 
pH 2 
PP 
27cm 
0.6x0.2x0.2 
Dihexyl ether 
NaOH 
pH 10 
Stirring 
300rpm 
15min 
FIA-CL 
[181] 
Ibuprofen 
Diclofenac 
Salicylic acid 
U 
50mL 
pH 2 
PP 
27cm 
0.6x0.2x0.2 
Dihexyl ether pH 12.5 
Stirring 
300rpm 
15min 
LC-UV 
LC-FD 
[140] 
Oxytetracycline 
Tetracycline 
Doxycycline 
P 
11mL 
pH ca. 9 
PP 
8.8cm 
0.6x0.2x0.2 
1-octanol + 10% (w/v) Aliquat-336 
0.1M H3PO4 + 1M NaCl  
pH 1.6 
Stirring 
900rpm 
35min 
LC-UV 
[182] Pioglitazone 
P 
U 
10mL 
pH 8 
10% (W/v) NaCl 
PP 
8.8cm 
0.6x0.2x0.2 
Dihexyl ether 
HCl 
pH 2.2 
Stirring 
500rpm 
30min 
LC-UV 
[94] Rosiglitazone 
P 
U 
10mL 
pH 9.5 
No salt added 
PP 
6cm 
0.6x0.2x0.2 
Dihexyl ether 
HCl 0.1M 
pH 1 
Stirring 
600rpm 
30min 
CE-UV 
LC-UV 
[81] 
Fluoxetine 
Norfluoxetine 
P 
5mL 
pH 14 
No salt added 
PP 
7cm 
0.6x0.2x0.2 
Dihexyl ether 
HCl 20mM 
pH 1.7 
Stirring 
1400rpm 
40min 
LC-FD 
[95] Gabapentin 
P 
U 
8.5mL 
No salt added 
FDNB 
PP 
8.8cm 
0.6x0.2x0.2 
Dihexyl ether pH 9.1 
Stirring 
1250rpm 
Room temperature 
45min 
LC-UV 
[150] 
Amitriptyline 
Citalopram 
Fluoxetine 
P 
70µL 
pH ca. 7.4 
PP 
2.9cm 
1.2x0.2x0.2 
1-ethyl-2-nitrobenzene 
HCOOH 10mM 
pH 2.9 
No forced convection 
9V 
1min 
LC-MS 
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Fluvoxamine 
[183] 
Ketoconazole 
Clotrimazole 
Miconazole 
P 
U 
10mL 
pH 11 
NaCl 5% (w/v) 
PP 
8cm 
0.6x0.2x0.2 
Dihexyl ether pH 2.5 
Stirring 
800rpm 
45min 
LC-UV 
[167] Amlodipine 
P 
U 
3mL 
pH 10 
PP 
8cm 
0.6x0.2x0.2 
NPOE 
HCl 10mM 
pH 2 
Stirring 
1000rpm 
200V 
15min 
CE-UV 
[96] Desipramine 
P 
U 
8mL 
pH 13 
No salt added 
PP 
5cm 
0.6x0.2x0.2 
Propyl benzoate 
HCl 1M 
pH 0 
Stirring 
700rpm 
Room temperature 
15min 
Voltametry 
[97] Phenazopyridine 
P 
U 
5mL 
pH 9 
No salt added 
PP 
3.5cm 
0.6x0.2x0.2 
Diphenyl ether 
H2SO4 0.1M 
pH 1 
Stirring 
1300rpm 
45oC 
30min 
FIA-DAD 
[184] Aristolochic acid U 
5mL 
pH 3 
PP 
3.3cm 
0.6x0.2x0.2 
1-octanol 
NaOH 10mM 
pH 12 
Stirring 
800rpm 
40min 
LC-UV 
[160] 
Aconitine 
Hypaconitine 
Mesaconitine 
U 
5mL 
pH 11 
PP 
5.3cm 
0.6x0.2x0.2 
1-octanol 
HCl 10mM 
pH 3 
Stirring 
800rpm 
40oC 
60min 
LC-UV 
[98] 
Matrine 
Sophocarpine 
U 
4mL 
pH 13.7 
No salt added 
PP 
7cm 
0.6x0.2x0.2 
1-octanol 
H3PO4 100mM 
pH 1.5 
Stirring 
600rpm 
60min 
LC-UV 
[62] 
Clotrimazole 
Miconazole 
P 
U 
24mL 
pH 8 
No salt added 
PP 
8cm 
0.6x0.2x0.2 
1-dodecane Acetonitrile 
Stirring 
900rpm 
40min 
GC-FID 
[99] Propylthiouracil 
P 
U 
7.5mL 
pH 12 
No salt added 
PP 
8.8cm 
0.6x0.2x0.2 
1-octanol + 6% (w/v) Aliquat 336 
NaClO4 2M 
pH 9 
Stirring 
1250rpm 
25oC 
40min 
LC-UV 
[100] Dexamethasone 
P 
U 
7.5mL 
pH 3 
No salt added 
PP 
8.8cm 
0.6x0.2x0.2 
1-octanol + 5% (w/v) Aliquat 336 
NaClO4 2M 
pH 9 
Stirring 
1250rpm 
Room temperature 
60min 
LC-UV 
[101] Desipramine 
P 
U 
8mL 
pH 13 
No salt added 
PP 
5cm 
0.6x0.2x0.2 
Propyl benzoate 
HCl 0.01M 
pH 2 
Stirring 
700rpm 
Room temperature 
15min 
Potentiometry 
[102] Mebendazole 
P 
U 
10mL 
pH 9 
No salt added 
PP 
8.8cm 
0.6x0.2x0.2 
1-undecanol 
HCl 100mM 
pH 1 
Stirring 
700rpm 
Room temperature 
60min 
LC-UV 
[102] Mebendazole 
P 
U 
7mL 
pH 1 
No salt added 
PP 
8.8cm 
0.6x0.2x0.2 
NPOE 
HCl 100mM 
pH 1 
Stirring 
700rpm 
Room temperature 
150V 
15min 
LC-UV 
[141] Ephedrine 
P 
U 
7mL 
pH 11 
NaCl 12% (w/v) 
PP 
7.5cm 
0.6x0.2x0.2 
Toluene + 10% (w/v) TEHP 
HCl 1mM 
pH 3 
Stirring 
1200rpm 
Room temperature 
LC-UV 
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25min 
[141] Ephedrine 
P 
U 
7mL 
pH 2 
PP 
7.5cm 
0.6x0.2x0.2 
NPOE + 10% (v/v) DEHP 
HCl 100mM 
pH 1 
Stirring 
1000rpm 
Room temperature 
100V 
15min 
LC-UV 
[172] Tramadol 
P 
U 
pH 11 
Ionic strength 4M 
PP 
10cm 
0.6x0.2x0.2 
1-dodecane Acetonitrile 
Stirring 
1000rpm 
40min 
GC-MS 
[164] 
Trimipramine 
Desipramine 
P 
U 
3mL 
pH ca. 12 
5% (w/v) NaCl 
PP 
1.3cm 
0.6x0.2x0.2 
1-dodecane 
Acetic acid 0.1M 
pH ca. 3 
Stirring 
860rpm 
45oC 
20min 
ESI-IMS 
[142] 
Naltrexone 
Nalmefene 
P 
U 
pH 2 
pH ca. 10 
PP 
5.6cm 
0.6x0.2x0.2 
NPOE + DEHP (85:15 v/v) 
HCl 100mM 
pH 1 
Stirring 
1250rpm 
100V 
20min 
LC-UV 
[103] Pentazocine 
P 
U 
3mL 
pH 9 
No salt added 
PP 
1.3cm 
0.6x0.2x0.2 
1-octanol 
Acetic acid 0.5M 
pH ca. 3 
Stirring 
900rpm 
20oC 
25min 
ESI-IMS 
[185] Clomipramine 
P 
U 
3mL 
pH ca. 10 
10% (w/v) NaCl 
PP 
3cm 
0.6x0.2x0.2 
1-dodecane Methanol 
Stirring 
1700rpm 
20min 
CD-IMS 
[104] 
Alfentanil 
Fentanyl 
Sufentanil 
P 
U 
5mL 
pH ca. 10 
No salt added 
PP 
3.5cm 
0.6x0.2x0.2 
Isoamyl benzoate 
H2SO4 0.05M 
pH 1.3 
Stirring 
1200rpm 
45oC 
20min 
LC-UV 
[105] Amantadine 
P 
U 
3mL 
pH ca. 10 
No salt added 
PP 
3cm 
0.6x0.2x0.2 
1-dodecane Methanol 
Stirring 
1400rpm 
20min 
CD-IMS 
[106] Amphetamines U 
3mL 
pH 3 
No salt added 
PP 
7cm 
0.6x0.2x0.2 
NPOE + 15% (v/v) TEHP 
HCl 100mM 
pH 1 
Stirring 
1000rpm 
Room temperature 
250V 
7min 
LC-UV 
[107] Thebaine U 
3mL 
pH 3 
No salt added 
PP 
6cm 
0.6x0.2x0.2 
NPOE 
HCl 100mM 
pH 1 
Stirring 
1250rpm 
300V 
15min 
LC-UV 
[77] 
Atenolol 
Betaxolol 
Propranolol 
OF 
3mL 
pH 3 
No salt added 
PP 
6cm 
0.6x0.2x0.2 
NPOE + 10% (v/v) DEHP + 5% 
(v/v)  TEHP 
HCl 100mM 
pH 1 
Stirring 
1250rpm 
250V 
15min 
LC-UV 
[78] Levamisole 
P 
U 
OF 
4mL 
pH 2 
No salt added 
PP 
9cm 
0.6x0.2x0.2 
NPOE + 5% (v/v) TEHP 
HCl 100mM 
pH 1 
Stirring 
1000rpm 
200V 
15min 
LC-UV 
[151] 
Atropine 
Scopolamine 
P pH 7.4 
PP 
10cm 
0.55x0.45x0.18 
1-heptanol:dimethyl benzene 
(30:70 v/v) 
HCl 50mM 
pH 1.3 
No forced convection 
37oC 
5h 
LC-UV 
[108] Nimesulide P 
5mL 
pH 2 
PP 
5.5cm 
Dihexyl ether 
NaOH 20mM 
pH 12.3 
Stirring 
400rpm 
LC-UV 
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No salt added Room temperature (25oC) 
30min 
[109] Bisoprolol P 
5.6mL 
pH ca. 14 
No salt added 
PVDF 
8.5cm 
0.6x0.2x0.2 
1-octanol 
Formic acid 1M 
pH 1.8 
Stirring 
800rpm 
35oC 
25min 
LC-FD 
[168] 
Imipramine 
Clomipramine 
P 
U 
2.1mL 
pH 4 
PP 
2.6cm 
0.6x0.2x0.2 
NPOE pH 2 
Stirring 
1400rpm 
200V 
20min 
GC-FID 
[110] Diclofenac 
P 
U 
2.1mL 
pH 11 
No salt added 
PP 
3.1cm 
1.2x0.2x0.2 
1-octanol 
NaOH 10mM 
pH 12 
Stirring 
1200rpm 
30oC 
20 V 
5min 
LC-UV 
[69] 
Butalbital 
Secobarbital 
Pentobarbital 
Phenobarbital 
B 
1mL 
pH ca. 1 
PP 
9cm 
0.6x0.2x0.2 
Decanol 
NaOH 
pH 13 
Sonication 
5min 
GC-MS 
[162] 
AMPAs 
MPA 
U 
3mL 
pH 1 
30% (w/v) NaCl 
PP 
3cm 
0.6x0.2x0.2 
1-octanol 
NaOH 
pH 14 
Stirring 
600rpm 
42oC 
50min 
LC-MS 
[82] Methimazole 
P 
U 
7.5mL 
pH 12.2 
CTAB 100mM 
No salt added 
PP 
8.8cm 
0.6x0.2x0.2 
Octanol NaClO4 1.5M 
Stirring 
1250rpm 
45oC 
50min 
LC-UV 
[162] 
Chloropheniramine 
Dextromethorphan 
P 
7.5mL 
pH 12.5 
2% (w/v) NaCl 
PP 
8.8cm 
0.6x0.2x0.2 
Hexadecane 
HCl 0.5mM 
pH 3.3 
Stirring 
1250rpm 
60min 
LC-UV 
[157] Basic drugs P 
50µL 
pH 7.4 
PP 
3cm 
0.6x0.2x0.2 
3 fibers 
NPOE 
Formic acid 10mM 
pH 2.9 
No forced convection 
200V 
10min 
LC-MS 
[111] 
Ofloxacin 
Ciprofloxacin 
P 
10mL 
pH 8.5 
No salt added 
PP 
8.8cm 
0.6x0.2x0.2 
1-octanol + 10% (w/v) Aliquat 336 
pH 1 
1mM NaCl 
Stirring 
1000rpm 
45min 
LC-UV 
[112] Trimipamine 
P 
U 
5mL 
pH 4.5 
No salt added 
PP 
8cm 
0.6x0.2x0.2 
NPOE pH 1 
Stirring 
1000rpm 
51V 
34min 
CE-UV 
[113] 
Amitriptyline 
Imipramine 
Trimipramine 
Clomipramine 
P 
U 
5mL 
pH 12 
No salt added 
PP 
8cm 
0.6x0.2x0.2 
1-dodecane 
Methanol + 
0.01M HCl 
pH 2 
Stirring 
1000rpm 
40min 
LC-UV 
[114] Mitiglinide 
P 
U 
10mL 
pH 1.5 
No salt added 
PP 
6cm 
0.6x0.2x0.2 
1-octanol 
NaOH 0.1M 
pH 13 
Stirring 
300rpm 
Room temperature 
45min 
LC-UV 
[115] Warfarin P 
11mL 
pH 2.3 
No salt added 
PP 
8.8cm 
0.6x0.2x0.2 
1-octanol 
0.1mM NaOH 
pH 11 
Stirring 
1000rpm 
30min 
LC-UV 
[116] Apigenin U 11mL PP 1-octanol Carbonate 50mM Stirring LC-UV 
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pH 3 
No salt added 
8.8cm 
0.6x0.2x0.2 
pH 11.5 1000rpm 
Room temperature 
75min 
[117] Amlodipine 
P 
U 
11mL 
pH 13 
No salt added 
PP 
8.8cm 
0.6x0.2x0.2 
Dibenzyl ether 
HCl 0.01M 
pH 2 
Stirring 
800rpm 
Room temperature 
45min 
LC-UV 
[70] 
Cathinone 
Amphetamines 
Ketamine 
DOI 
B 
HB 
80µL 
PP 
5cm 
0.6x0.2x0.2 
ENB 
Acetic acid 10mM 
pH 3.4 
No forced convection 
15V 
5min 
LC-MS 
[186] 
Dextromethorphan 
Pseudoephedrine 
P 
U 
3mL 
pH 12.7 
0% and 30% (w/v) 
NaCl for 
dextromethorphan 
and 
pseudoephedrine 
PP 
3cm 
0.6x0.2x0.2 
1-dodecane Methanol 
Stirring 
750rpm 
20min 
CD-IMS 
[118] 
Hydroxyzine 
Cetirizine 
P 
10mL 
pH 5 → 11 
No salt added 
PP 
8.2cm 
0.6x0.2x0.2 
1-octanol pH 2 
Stirring 
1200rpm 
Room temperature 
30min and then 20min 
CE-UV 
[79] Amphetamines H 
50mg 
pH 14 
1% (w/v) NaCl 
PP 
9cm 
0.6x0.2x0.2 
Dihexyl ether 
HCl 0.1M 
pH 1 
Vibrating 
1000rpm 
45min 
GC-MS 
[119] Desipramine 
P 
U 
3mL 
pH ca. 13 
No salt added 
PP 
0.8cm 
0.6x0.2x0.2 
1-dodecanol Methanol 
Stirring 
900rpm 
Room temperature 
25min 
GC-NPD 
[120] 
Nalmefene 
Diclofenac 
U 
24mL 
Neutral pH (6.5) 
No salt added 
PP 
3.8cm 
0.6x0.2x0.2 
2 fibers 
NPOE + 5% (v/v) DEHP 
1-octanol 
HCl 50mM 
pH 1.3 
NaOH 50mM 
pH 12.7 
Stirring 
700rpm 
40V 
Room temperature 
14min 
LC-UV 
[152] 
Pethidine 
Diphenhydramine 
Nortriptyline 
Methadone 
U 
1mL 
pH 12.6 
PP 
20mm 
1.2x0.2x0.2 
1-octanol 
HCl 10mM 
pH 2 
Vibrating 
1000rpm 
30min 
DESI-MS 
[121] Sufentanil 
P 
U 
4mL 
pH 2.5 
No salt added 
PP 
8cm 
0.6x0.2x0.2 
NPOE 
HCl 0.1M  
pH 1 
Stirring 
1000rpm 
190V 
28min 
Voltametry 
[143] Dexamethasone 
P 
U 
7.5mL 
pH 6 
PP 
3.3cm 
0.6x0.2x0.2 
1-octanol + 5% (w/v) Aliquat 336 
NaClO4 0.65 M 
pH 10 
Stirring 
500rpm 
80min 
LC-UV 
[122] Metformin 
P 
U 
10mL 
pH 13.4 
PFBC 10mg 
No salt added 
PP 
4cm 
0.6x0.2x0.2 
Dihexyl ether 
HCl 100mM 
pH 1 
Stirring 
300rpm 
70oC 
30min 
LC-UV 
[165] NSAID U 
4mL 
pH 3 
10% (w/v) NaCl 
PP 
4cm 
0.6x0.2x0.2 
Dihexyl ether pH 13 
Stirring 
1500rpm 
60oC 
45min 
LC-UV 
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[123] 
Venlafaxine and 
metabolites 
P 
4mL 
pH 10 
No salt added 
PP 
15cm 
0.6x0.2x0.2 
1-octanol 
Acetic acid 0.1M 
pH ca. 3 
Stirring 
1750rpm 
20min 
LC-MS/MS 
[169] Tolterodine 
P 
U 
3mL 
pH 2 
PP 
8cm 
0.6x0.2x0.2 
NPOE 
HCl 500 mM 
pH 0.3 
Stirring 
1200rpm 
54V 
20oC 
24min 
CE-UV 
[187] Ketoprofen P 
5mL 
pH 2 
5% (w/v) NaCl 
PP 
8cm 
0.6x0.2x0.2 
1-octanol pH 11 
Stirring 
600rpm 
Room temperature 
30min 
LC-UV 
[135] Trimetazidine P 
2.1mL 
pH 14 
250mM sodium 
1-octanesulfonate 
7% (w/v) Na2SO4 
PP 
10cm 
0.6x0.2x0.2 
1-octanol 
HCl 0.5M 
pH 0.3 
Stirring 
600rpm 
25min 
LC-UV 
[80] 
Butalbital 
Secobarbital 
Pentobarbital 
Phenobarbital 
L 
1mL 
pH 1.1 
PP 
9cm 
0.6x0.2x0.2 
Eucalyptus oil 
NaOH 0.1M 
pH 13 
Sonicating 
5min 
GC-MS 
[136] NSAID U pH 2 
PP 
13cm 
0.6x0.2x0.2 
Dihexyl ether pH 12 
Stirring 
300rpm 
20min 
CE-UV 
[136] Sulfonamides U 
50mL 
pH 4 
28% (w/v) Na2SO4  
PP 
27cm 
0.6x0.2x0.2 
1-octanol pH 12 
Stirring 
300rpm 
6h 
LC-UV 
LC-FD 
[144] Morphine U 
4mL 
pH 6 
PP 
8cm 
0.6x0.2x0.2 
NPOE + 10% (v/v) TEHP + 10% 
(v/v) DEHP 
HCl 0.1M 
pH 1 
Stirring 
1000rpm 
90V 
24min 
DPV 
[155] 
Ketamine 
Norketamine 
Dehydronorketamine 
U 
pH 10 
10% (w/v) NaCl 
PP 
7.5cm 
0.6x0.2x0.2 
Eucalyptus essential oil 
HCl 1 M 
pH 0 
Vibrating 
2400rpm 
30min 
GC-MS 
[153] 
Pyrethroid and 
metabolites 
U 
1.2mL 
pH 4 
Conc. HCl 
8.3% (w/v) NaCl 
PP 
1cm 
1.67x0.52x0.33 
Dihexyl ether 
NaOH 0.1M 
pH 13 
120min LC-UV 
[71] 
TCA 
Desmethylclomipram
in 
Fluoxetine 
Norfluoxetine 
B 
4mL 
pH ca. 13 
PP 
8cm 
0.6x0.2x0.2 
Dodecane 
Formic acid 0.1M 
pH 2.4 
Stirring 
1200rpm 
55oC 
30min 
GC-MS 
[124] Dextromethorphan 
P 
U 
4mL 
pH 6 
No salt added 
PP 
8cm 
0.6x0.2x0.2 
NPOE 
HCl 0.1M 
pH 1 
Stirring 
1000rpm 
110V 
20min 
DPV 
[125] Pramipexole 
P 
U 
10mL 
pH 11.5 
No salt added 
PP 
4cm 
0.6x0.2x0.2 
1-octanol pH 3 
Stirring 
600rpm 
25oC 
40min 
LC-UV 
[126] 
Methamphetamine 
Cocaine 
U 
4mL 
pH 6.5 
PP 
5cm 
NPOE + 10% (v/v) DEHP + 10% 
(v/v) TEHP 
pH 1 
pH 12 
Stirring 
1000rpm 
CE-UV 
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Methadone 
Buprenorphine 
Morphine 
Ibuprofen 
Ketoprofen 
Enalapril 
No salt added 0.6x0.2x0.2 
4 fibers 
1-octanol 
1-octanol + 4% (w/v) CTAB 
NPOE 
50V 
15min 
[47] Atorvastatin U 
24mL 
pH 4 
1.2% (w/v) NaCl 
PP 
8.5cm 
0.6x0.2x0.2 
1-octanol 
NaOH 0.001M 
pH 11 
Stirring 
1000rpm 
60min 
LC-UV 
[127] Carbegoline 
P 
U 
15mL 
pH 10 
No salt added 
PP 
8cm 
0.6x0.2x0.2 
1-octanol pH 3 
Stirring 
750rpm 
Room temperature (25oC) 
30min 
LC-UV 
[158] 
Aristolochic acid I 
Aristolochic acid II 
P 
4mL 
pH 3 
2% (w/v) NaCl 
PP 
6cm 
0.6x0.2x0.2 
1-octanol pH 11 
Stirring (magnetofluid) 
2000rpm 
Room temperature (25oC) 
8min 
LC-FD 
[128] 
Berberine 
Palmatine 
P 
U 
3mL 
pH 11.8 
No salt added 
PP 
8cm 
0.6x0.2x0.2 
1-octanol 
HCl 0.1M 
pH 1 
Stirring 
600rpm 
25oC 
10min 
CE-UV 
[170] Propranolol 
P 
U 
4mL 
pH 3.5 
PP 
8cm 
0.6x0.2x0.2 
NPOE pH 1 
Stirring 
1250rpm 
40V 
20oC 
32min 
CE-UV 
[174] THC-COOH U 
1mL 
pH < 3 
1% (w/v) NaCl 
PP 
9cm 
0.6x0.2x0.2 
Dihexyl ether 
NaOH 0.1mM 
pH 10 
Shaking 
1200rpm 
30min 
GC-MS 
[173] 
Cocaine 
Ketamine 
Lidocaine 
U 
14mL 
pH 11 
20% (w/v) NaCl 
PP 
10cm 
0.6x0.2x0.2 
1-dodecane Acetonitrile 
Stirring 
700rpm 
30min 
GC-MS 
[76] Lidocaine 
Se 
U 
5mL 
pH ca. 12 
1% (w/v) KCl 
PP 
8.2cm 
0.6x0.2x0.2 
1-octanol 
HCl 0.01M 
pH ca. 2 
Stirring 
1000rpm 
Room temperature 
50min 
LC-UV 
[129] 
Rosiglitazone 
Metformin 
P 
U 
10mL → 10.7mL 
pH 9 → ca. 14 
No salt added 
No derivitizing agent 
→ 10mg/mL PFBC 
(100uL) 
4cm Dihexyl ether 
HCl 0.1M 
pH 1 
Stirring 
300rpm 
Room temperature → 70oC 
30 min+30min 
LC-UV 
[130] Citalopram U 
4mL 
pH 12.5 
No salt added 
PP 
8.0cm 
0.6x0.2x0.2 
1-octanol pH 2.2 
Stirring 
1000rpm 
28min 
CE-UV 
[49] Triamterene U 
24mL 
pH 14 
11% (w/v) NaCl 
PP 
8.5cm 
0.6x0.2x0.2 
1-decanol pH 1 
Stirring 
800rpm 
90min 
LC-UV 
[131] 
Olanzapine 
Fluoxetine 
U 
P 
3mL 
pH 12 
5% (w/v) NaCl 
PP 
2.8cm 
1.2x0.2x0.2 
1-octanol 
HCl 25 or 10mM 
pH 1.6 or 2 
Stirring 
1000rpm 
60min 
LC-UV 
[131] 
Olanzapine 
Fluoxetine 
U 
P 
3mL 
pH 6 
PP 
2.8cm 
NPPE 
HCl 10mM 
pH 2 
Stirring 
1000rpm 
LC-UV 
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No salt added 1.2x0.2x0.2 200V 
30min 
[161] Benzodiazepines U 
2mL 
pH 10 
10% (w/v) NaCl 
PP 
9cm 
0.6x0.2x0.2 
Dihexyl ether:1-nonanol (9:1 v/v) 
HCl 3M 
pH 0 
Vibrating 
2400rpm 
90min 
GC-MS 
[132] 
Diclofenac 
Naproxen 
U 
P 
4mL 
pH 7.4 
Triton X-100 0.2mM 
No salt added 
PP 
6cm 
0.6x0.2x0.2 
1-octanol pH 12 
Stirring 
1000rpm 
15V 
15min 
CE-UV 
[171] Phenazopyridine 
U 
P 
6.5mL 
Neutral pH 
PP 
7.5cm 
0.6x0.2x0.2 
NPOE 
HCl 100mM 
pH 1 
Stirring 
1250rpm 
100V 
20min 
LC-UV 
[154] 
Atrazine and 
degradation products 
U 
200mL 
pH 7 
20% (w/v) NaCl 
PP 
20cm 
0.28x0.05x0.1 
Dihexyl ether 
HCl 1M 
pH0 
Stirring 
150rpm 
Room temperature (ca. 20) 
5h 
LC-UV 
[166] Sitagliptin U 
15mL 
pH 10.5 
35% (w/v) NaCl 
PP 
8.5cm 
0.6x0.2x0.2 
1-octanol pH 3 
Stirring 
1000rpm 
25oC 
50min 
LC-UV 
[133] 
Atorvastatin 
Lovastatin 
Simvastatin 
U 
18mL 
pH 2 
No salt added 
PP 
10cm 
0.6x0.2x0.2 
1-dodecane + 5% (w/v) TOPO 
Methanol + NaOH 0.1M 
pH 13 
Stirring 
1000rpm 
45min 
LC-UV 
GC-FID 
[145] 
Levonogestrel 
Megestrol 
U 
20mL 
No pH adjustment 
10% (w/v) NaCl 
PP 
8cm 
0.6x0.2x0.2 
1-dodecane + 5% (w/v) TOPO Methanol 
Stirring 
1000rpm 
40min 
LC-UV 
[188] SSRI 
P 
U 
6mL 
pH 12.8 
2% (w/v) NaCl 
PP 
3cm 
0.6x0.2x0.2 
Phenetole 
Acetic acid 0.1M 
pH ca. 3 
Stirring 
1000rpm 
40min 
Sweeping-
MEKC 
[56] 
Albendazole 
Triclabendazole 
U 
6mL 
pH 8 
No salt added 
PP 
8.8cm 
0.6x0.2x0.2 
1-undecanol 1-undecanol 
Vibrating 
3min 
LC-FD 
[74] 
Codeine 
Naproxen 
Ketamine 
Ibuprofen 
P 
M 
4mL 
pH 6 
PP 
2.1cm 
1.2x0.3x0.2 
1-octanol (acidic) 
2-ethyl hexanol (basic) 
 
Stirring 
750rpm 
175V 
25min 
LC-UV 
[74] 
Codeine 
Naproxen 
Ketamine 
Ibuprofen 
P 
M 
4mL 
pH 6 
PP 
2.1cm 
1.2x0.3x0.2 
1-octanol (acidic) 
2-ethyl hexanol (basic) 
HCl 32mM  
pH 1.5 (basic) 
NaOH 32mM  
pH 12.5 (acidic) 
Stirring 
750rpm 
150V  
6min  
400V  
19min 
LC-UV 
[134] Clozapine P 
30mL 
pH 4.5 
No salt added 
PP 
10cm 
1.2x0.3x0.2 
NPOE pH 4.5 
Stirring 
1000rpm 
200V 
18min 
Voltametry 
[146] Nalidixic acid U 
5mL 
pH ca. 12 
PP 
10cm 
0.6x0.2x0.2 
1-octanol + Aliquat 336 (9:1 v/v) NaCl 1M 
Stirring 
1000rpm 
ca. 25oC 
45min 
LC-UV 
[74] 
Ketamine (B) 
Codenie (B) 
P 
M 
4mL 
pH 6 
PP 
2.1cm 
2-ethyl hexane (B) 
1-octanol (A) 
HCl pH 1.5 (B) 
NaOH pH 12.5 (A) 
Stirring 
750rpm 
LC-UV 
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Naproxene (A) 
Ibuprofen (A) 
1.2x0.3x0.2 150V 6min (A) → 400V 
19min (B) 
[84] Lamotrigine P 
4mL 
pH 9 
No salt added 
PP 
15cm 
0.6x0.2x0.2 
1-octanol HCl pH 4 
Stirring 
500rpm 
30min 
Room T 
CE-UV 
[58] 
Oxazepam 
Lorazepam 
U 
P 
25mL 
No pH adjustment 
PP 
7cm 
0.6x0.2x0.2 
n-dodecane + TOPO 7.5% (w/v) Acetonitrile 
Stirring 
1000rpm 
30min 
LC-MS 
[83] 
Muscimol 
Tryptophan 
Tryptamine 
U 
10mL 
pH 4 
No salt added 
PP 
8cm 
0.6x0.2x0.2 
Dihexyl ether + DEHPA 20% 
(w/w) 
HCl 200mM 
Stirring 
800rpm 
60min 
LC-UV 
[49] Triamterene U 
24mL 
NaOH 3M 
2M NaCl 
PP 
8.5cm 
0.6x0.2x0.2 
1-decanol HCl pH 1 
Stirring 
800rpm 
90min 
LC-UV 
[85] 
Ibuprofen 
Diclofenac 
U 
4mL 
pH 10.5 
No salt added 
PP 
6cm 
0.6x0.2x0.2 
1-octanol + 0.6% w/v C60 
fullerene 
NaOH pH 12.8 
Stirring 
1000rpm 
28min 
6V 
LC-UV 
[147] Bismuth P 
5mL 
5mM H2SO4 
PP 
3.5cm 
0.6x0.2x0.2 
1-octanol + 1% (v/v) DEHP 300mM H2SO4 
Stirring 
700rpm 
10min 
70V 
UV-Vis 
[86] Diclofenac 
U 
P 
0.05M HCl 
No salt added 
PP 
2.5cm 
0.6x0.2x0.2 
n-dodecane Methanol 
Stirring 
1000rpm 
20min 
Room T 
ESI-IMS 
Table 3. 3-phase HF-LPME (and variants) of drugs of forensic interest in biological matrices. The concentration values of salt added were converted to % (w/v); 
the pH were calculated based on the concentration of base or acid in some cases. Abbreviations: (A) = acidic; Aliquat-336 = 3-caprylil methyl ammonium chloride; 
AMPAs = alkyl methylphosphonic acids; (B) = basic; B = whole blood; ca. = approximately; CE = capillary electrophoresis; DEHP = di-(2-ethylhexyl) phosphate; 
DOI = 2,5-dimethoxy-4-iodoamphetamine; FD = fluorescent detector; FDNB = 1-fluoro-2,4-dinitrobenzene; FIA = flow injection analysis; FID = flame ionization 
detector; GC = gas chromatography; H = hair; HB = haemolysed blood; id = internal diameter; L = liver; LC = high performance liquid chromatography; M = 
breast milk; MEKC = micellar electrokinetic chromatography; MPA = methylphosphonic acid; MS = mass spectrometry; MS/MS = tandem mass spectrometry; 
n.r. = not reported; Na2SO4 = sodium sulfate; NaCl = sodium chloride; NDCIT = N-desmethylcitalopram; NPD = nitrogen-phosphorus detector; NPOE = 2-
nitrophenyl octylether; OF = oral fluid; P = plasma; PP = polypropylene; ps = pore size; PVDF = polyvinylidene difluoride; Se = serum; SSRI = selective serotonin 
reuptake inhibitors; T = temperature; THC-COOH = 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid; TCA = tricyclic antidepressants; TEHP = tris(2-
ethylhexy)phosphate; TOPO = trioctylphosphine oxide; wt = wall thickness; U = urine; UV = ultra-violet; Vis = visible 
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3. Challenges and future prospects 
This systematic review searched deeply for papers that comprised of 
bioanalytical methods involving HF-LPME. The number of methods 
included in the review shows how attractive the technique is, mainly 
due to its low cost and green chemistry approach. 
Future work should include various classes of drugs to show the 
versatility of HF-LPME, and how it can be a good alternative to the 
routine methods of forensic toxicology laboratories. As can be seen in 
the systematic review, many methods involving some classes of drugs 
have been published, including benzodiazepines, stimulants, and antihypertensives; 
however, other classes of drugs still lack of evidence to 
show the applicability of HF-LPME in bioanalysis, such as for carbamates, 
NBOMe, and synthetic cannabinoids. 
In addition to that, the comparison between different forced convection 
methods can be further explored. Besides that, only few studies 
(10 methods of all the methods compiled) used whole blood as matrix; 
further study of this important matrix for forensic toxicology should be 
undertaken to better understand the interaction between this complex 
matrix and the HF-LPME. More work can also be undertaken towards 
improving the possibility for automation of the technique, which is still 
very manual. The development of commercial equipment and kits to 
decrease the manual labour involved in the extraction would help the 
adoption of HF-LPME in routine analyses. Through automation, in addition 
to facilitating the work, human error can be decreased, increasing 
reproducibility and precision of the analyses. 
Besides, variants of the technique using hollow-fibers are also attractive 
and have been explored in different fields of analytical chemistry. 
An example of these variants is the Parallel Artificial Liquid 
Membrane Extraction (PALME), where, instead of hollow fibers, flat 
porous membranes are used to support the solvent during extraction. 
This technique showed good results in the extraction of several analytes, 
including different NPS and polar drugs. Commercial availability 
of plates for PALME would also facilitate the procedure [189–191]. 
The addition advantage of the use of supramolecular solvents or 
essential oils, in terms of green-chemistry, can also be further explored 
in future works to reinforce the environmental-friendliness of the 
method. 
4. Conclusions 
All research related to new extraction methods, and specifically to 
HF-LPME, shows that this technique is a powerful method during 
sample preparation in bioanalysis. The increasing number of published 
articles over the years shows how acceptable HF-LPME has become in 
laboratories that perform analyses of biological material. 
The advantages of HF-LPME over traditional extraction methods 
bring several benefits to numerous fields of toxicology, including forensic 
toxicology, and should facilitate complex sample handling. Due to 
the disposable nature of the fibers the problem related to carryover 
present in SPME is eliminated. Also due to the capacity of the fiber to 
efficiently separate the matrix from the analyte, it is good at decreasing 
the matrix effects, and providing the cleaning-up of the samples, 
thereby making it possible to use the extraction technique with complex 
matrices [15]. Moreover the ratio between the volumes of the donor 
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and acceptor phases in HF-LPME is very high, making the enrichment 
factor of HF-LPME high [7]. Besides that, the extraction method is 
highly selective, relatively simple, cheap, and is linked to green 
chemistry [6,7,12,192]. Another advantage is that the technique combines 
extraction and concentration in one step, something not possible 
with other methods, such as LLE and SPE. On the other hand, it is 
usually not an exhaustive method and may present poor reproducibility 
due to manual cutting and sealing of the membrane [15]. Moreover, 
many articles cited the difficulty of dealing with small volumes of solvents 
and of extracting many drugs simultaneously. 
HF-LPME clearly presents a high application potential for routine 
testing in analytical toxicology laboratories. It is the potential for automation 
and its versatility regarding the suitability to different matrices 
and analytes place the technique in the bright list of methods with 
high potential to be adopted in forensic toxicology laboratories. By 
opening the new perspectives in sample preparation, the HF-LPME offers 
promising results for the field. 
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